Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial

Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial

Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial
Investigational trial results support potential that haploidentical stem cell transplant may be a treatment option for a broader pediatric patient population
July 8, 2019

2019-07-16T13:33:02-05:00July 8th, 2019|

About the Author:

Leave A Comment